NeoStem's Progenitor Cell Therapy Enters Deal for Cell Therapy Manufacturing Services

by Benzinga Staff
January 16, 2013 8:08 AM | 17 seconds read | Make a Comment

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

NeoStem, Inc. (NYSE: NBS) and its subsidiary, Progenitor Cell Therapy LLC("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively,"Adaptimmune"), announced today a Services Agreement under which PCT willprovide services to support Adaptimmune's NYESO-1^c259-T cell therapy productbeing developed for multiple oncology indications (for more information withrespect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiersNCT01350401, NCT01343043 and NCT01352286).

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsContracts

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.